- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07629284
Home-Based Tele-Rehabilitation for Respiratory Function in Children With Duchenne Muscular Dystrophy
June 1, 2026 updated by: Jeong Yi Kwon, Samsung Medical Center
Feasibility and Preliminary Clinical Effects of a Home-Based, Remotely Delivered Respiratory Rehabilitation Program for Children With Duchenne Muscular Dystrophy
This study evaluates the feasibility and preliminary clinical effects of a home-based tele-rehabilitation program aimed at improving respiratory function in children with Duchenne Muscular Dystrophy (DMD).
Study Overview
Status
Enrolling by invitation
Conditions
Intervention / Treatment
Detailed Description
This is a prospective single-arm interventional study evaluating a 6-week home-based tele-rehabilitation program for respiratory function in children with Duchenne Muscular Dystrophy.
The intervention includes weekly remote education sessions and home-based exercises, with assessments conducted before and after the intervention and a 2-week follow-up for adherence monitoring.
Study Type
Interventional
Enrollment (Estimated)
12
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Seoul
-
Seoul, Seoul, South Korea, 06351
- Samsung Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Children aged 3 years or older with genetically confirmed Duchenne muscular dystrophy
- Participants who are able to understand the study procedures and appropriately participate in the study
Exclusion Criteria:
- Requirement for daytime ventilator support or invasive mechanical ventilation via tracheostomy (nighttime non-invasive ventilation such as positive airway pressure ventilation is allowed)
- History of peripheral nerve injury
- History of major surgery within 12 weeks prior to enrollment or expected major surgery during the study period
- History of central nervous system disorders (e.g., cerebral infarction or spinal cord injury)
- Severe cognitive impairment or other conditions that may interfere with participation in the study procedures
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Home-Based Telerehabilitation Group
Participants with Duchenne muscular dystrophy will receive a 6-week home-based telerehabilitation respiratory program including weekly remote education sessions, caregiver-assisted respiratory exercises, self-directed home exercises, and exercise log monitoring.
Outcomes will be assessed at pre-intervention, post-intervention, and 2-week follow-up.
|
A 6-week caregiver-assisted home-based respiratory telerehabilitation program for children with Duchenne muscular dystrophy.
The program includes weekly remote education sessions, respiratory muscle exercises, airway clearance training, relaxation positioning, and self-directed home exercises performed at least 5 times per week.
Outcomes are assessed before and after the intervention and at 2-week follow-up.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Feasibility of the Home-Based Respiratory Tele-rehabilitation Program
Time Frame: Baseline to immediately after the 6-week intervention
|
Feasibility of the home-based respiratory telerehabilitation program will be assessed using exercise adherence rate, session attendance rate, and exercise log completion during the 6-week intervention period.
These measures will be summarized descriptively as indicators of program feasibility.
Higher percentages indicate better feasibility.
|
Baseline to immediately after the 6-week intervention
|
|
Acceptability of the Home-Based Respiratory Tele-rehabilitation Program
Time Frame: Immediately after the 6-week intervention and at 2-week follow-up
|
Acceptability of the home-based respiratory telerehabilitation program will be assessed using caregiver-reported satisfaction, perceived exercise difficulty, caregiver burden, and child participation questionnaires during the intervention period.
Higher satisfaction and participation scores indicate greater acceptability, whereas higher perceived difficulty and caregiver burden scores indicate lower acceptability.
|
Immediately after the 6-week intervention and at 2-week follow-up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Inspiratory Muscle Strength
Time Frame: Baseline and immediately after the 6-week intervention
|
Inspiratory muscle strength will be assessed using maximal inspiratory pressure (MIP).
Measurements will be recorded in centimeters of water pressure (cmH2O).
Higher values indicate greater inspiratory muscle strength.
|
Baseline and immediately after the 6-week intervention
|
|
Expiratory Muscle Strength
Time Frame: Baseline and immediately after the 6-week intervention
|
Expiratory muscle strength will be assessed using maximal expiratory pressure (MEP).
Measurements will be recorded in centimeters of water pressure (cmH2O).
Higher values indicate greater expiratory muscle strength.
|
Baseline and immediately after the 6-week intervention
|
|
Respiratory Muscle Function
Time Frame: Baseline and immediately after the 6-week intervention
|
Respiratory muscle function will be assessed using inspiratory muscle endurance time, surface electromyography (sEMG) of the sternocleidomastoid muscle, and respiratory muscle ultrasonography.
Inspiratory muscle endurance will be measured in seconds, and respiratory muscle thickness will be measured in millimeters (mm).
Higher endurance time and greater muscle thickness indicate improved respiratory muscle function.
|
Baseline and immediately after the 6-week intervention
|
|
Physical Functional Performance
Time Frame: Baseline and immediately after the 6-week intervention
|
Physical functional performance will be assessed using the Vignos Scale, Brooke Upper Extremity Functional Rating Scale, and North Star Ambulatory Assessment (NSAA).
The Vignos Scale ranges from 1 to 10, with higher scores indicating greater lower extremity disability.
The Brooke Scale ranges from 1 to 6, with higher scores indicating greater upper extremity functional limitation.
The NSAA ranges from 0 to 34, with higher scores indicating better motor function.
|
Baseline and immediately after the 6-week intervention
|
|
Functional Exercise Capacity
Time Frame: Baseline and immediately after the 6-week intervention
|
Functional exercise capacity will be assessed using the 6-Minute Walk Test (6MWT).
Total walking distance will be recorded in meters.
Greater walking distance indicates better functional exercise capacity.
|
Baseline and immediately after the 6-week intervention
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 23, 2026
Primary Completion (Estimated)
February 28, 2027
Study Completion (Estimated)
March 31, 2027
Study Registration Dates
First Submitted
May 20, 2026
First Submitted That Met QC Criteria
June 1, 2026
First Posted (Actual)
June 5, 2026
Study Record Updates
Last Update Posted (Actual)
June 5, 2026
Last Update Submitted That Met QC Criteria
June 1, 2026
Last Verified
June 1, 2026
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2025-12-123
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Duchene Muscular Dystrophy
-
Cairo UniversityNot yet recruiting
-
Nantes University HospitalAGENCE NATIONALE DE RECHERCHENot yet recruitingBecker Muscular Dystrophy | Duchene Muscular Dystrophy
-
Avidity Biosciences, Inc.Not yet recruitingNervous System Diseases | Musculoskeletal Diseases | Muscular Dystrophies | Muscular Disorders, Atrophic | Genetic Diseases | Neonatal Disease | X-Linked | DMD | Hereditary | Muscular Dystrophies (Duchenne, Becker, Myotonic Dystrophy) | Muscular Disease | Congenital | Neuromuscular Diseases (NMD) | Duchene Muscular...
-
ITF Therapeutics LLCRecruitingDuchene Muscular DystrophyUnited States
-
Avidity Biosciences, Inc.RecruitingFacioscapulohumeral Muscular Dystrophy | FSHD | Facioscapulohumeral Muscular Dystrophy Type 1 (FSHD1) | Facio-Scapulo-Humeral Dystrophy | FSHD - Facioscapulohumeral Muscular Dystrophy | Facioscapulohumeral Muscular Dystrophy 1 | FSHD2 | FSHD1 | Fascioscapulohumeral Muscular Dystrophy | Fascioscapulohumeral... and other conditionsUnited States, Denmark, Spain, Canada, United Kingdom, Italy, Germany, France, Japan, Netherlands
-
Avidity Biosciences, Inc.CompletedMuscular Dystrophies | Muscular Dystrophy, Facioscapulohumeral | FSHD | Facio-Scapulo-Humeral Dystrophy | FMD | Facioscapulohumeral Muscular Dystrophy 1 | FSHD2 | FSHD1 | FMD2 | Fascioscapulohumeral Muscular Dystrophy | Fascioscapulohumeral Muscular Dystrophy Type 1 | Fascioscapulohumeral Muscular Dystrophy... and other conditionsUnited States, Canada, United Kingdom
-
Avidity Biosciences, Inc.Active, not recruitingMuscular Dystrophies | Muscular Dystrophy, Facioscapulohumeral | FSHD | Facio-Scapulo-Humeral Dystrophy | FMD | Facioscapulohumeral Muscular Dystrophy 1 | FSHD2 | FSHD1 | FMD2 | Fascioscapulohumeral Muscular Dystrophy | Fascioscapulohumeral Muscular Dystrophy Type 1 | Fascioscapulohumeral Muscular Dystrophy... and other conditionsUnited States, Canada, United Kingdom
-
FSHD SocietyRecruitingFacioscapulohumeral Muscular Dystrophy | Muscular Dystrophy, Facioscapulohumeral | FSHD | Facioscapulohumeral Muscular Dystrophy (FSHD) | FSHD - Facioscapulohumeral Muscular Dystrophy | Facioscapulohumeral Muscular Dystrophy 1 | FSHD2 | FSHD1 | Facioscapulohumeral Muscular Dystrophy 2 | FSH Muscular Dystrophy and other conditionsUnited States
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedBecker Muscular Dystrophy | Facioscapulohumeral Muscular Dystrophy | Limb-Girdle Muscular DystrophyUnited States
-
University of North Carolina, Chapel HillNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and other collaboratorsCompletedMuscular Dystrophies | Duchenne Muscular Dystrophy | Becker Muscular Dystrophy | Limb-Girdle Muscular DystrophyUnited States
Clinical Trials on Home-Based Respiratory Telerehabilitation Program
-
Necmettin Erbakan UniversityCompleted
-
Hacer Önen TekinCompleted
-
MedicAir Healthcare S.r.l.RecruitingObesity | Bronchiectasis | Chronic Obstructive Pulmonary Disease | Asthma | Respiratory Disease | Long COVID | Lung FibrosisItaly
-
Hospital Universitari Vall d'Hebron Research InstituteNora Therapeutics, Inc.; MuvityNot yet recruiting
-
Institute of Cardiology, Warsaw, PolandNational Center for Research and Development, PolandCompletedChronic Heart FailurePoland
-
Istituto Ortopedico RizzoliCompleted
-
Hacettepe UniversityCompleted
-
Ekin AkpınarCompleted
-
Izmir Democracy UniversityCompletedRotator Cuff Injuries | Rotator Cuff TendinitisTurkey
-
Saglik Bilimleri UniversitesiCompleted